News

Last week at CARSTAR’s annual Evolution Conference in Montreal, Quebec, Cystic Fibrosis Canada and the collision and glass service organization celebrated the milestone of 25 years of partnership.

Cystic Fibrosis Canada’s Chief Scientific Officer, Dr. Paul Eckford, recently attended the European CF Society’s annual conference where important advances in research and clinical care were shared.   

Cystic Fibrosis Canada’s Healthcare Advisory Council has published recommendations for the follow-up of pregnancies and newborns of mothers who are receiving cystic fibrosis transmembrane conductance regulator (CFTR) modulators, like Trikafta.  

Cystic Fibrosis Canada has awarded nearly $2.7M in research funding to projects that support the organization’s new approach to research funding, aimed at improving health outcomes for people living with cystic fibrosis (CF).

Cystic Fibrosis Canada’s Healthcare Advisory Committee (HAC) has published standardized Canadian care guidelines?for the diagnosis and treatment of pulmonary exacerbations in patients with cystic fibrosis.

We are pleased to share our 2022-2023 Impact Report and celebrate the work our community helped us to achieve on behalf of Canadians with cystic fibrosis.  

Cystic Fibrosis Canada asks participants to go #FurtherForAll Canadians with cystic fibrosis

Cystic Fibrosis Canada’s Broken Arrow Conference kicks off a new approach to balancing patient needs with impactful, high-quality research

Cystic Fibrosis Canada calls on the provinces and territories to implement strategy and improve access today

Report finds nearly 25% of Canadians with CF are taking a CFTR modulator therapy